검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | AA (Abiraterone acetate, Abiraterone acetate (AA)) Janssen Research & Development, LL…·Metastatic Castration-sensitive Pr… ORR 57.1%·t½ 3.2 h |
|---|---|
Overview Program | Abiraterone acetate (AA) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | CGT |
Overview Target | Metastatic Castration-sensitive Prostate |
Overview Indication | Metastatic Castration-sensitive Prostate Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targets, and regulatory pathway |
MoA Biomarker | biomarker source |
PK/PD Half-life | 3.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Influence of drug incorporation strategy on structure and release behavior of alginate beads: A mechanistic study.. Conventional excipients used in pharmaceutical formulations often exhibit limitations such as uncontrolled drug release and adverse patient responses, highlighting the need for improved drug delivery systems. Sodium alginate beads have been widely investigated as biocompatible carrie… |
Clinical Primary efficacy | ORR 57.1% |
Clinical ORR | 57.1% |
Clinical PFS | 16.16 |
Clinical OS | 34.07 |
Clinical Result source | ClinicalTrials.gov NCT01867710 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | AA (Abiraterone acetate, Abiraterone acetate (AA)) Janssen Research & Development, LL…·Metastatic Castration-sensitive Pr… ORR 57.1%·t½ 3.2 h |
|---|---|
Overview Program | Abiraterone acetate (AA) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | CGT |
Overview Target | Metastatic Castration-sensitive Prostate |
Overview Indication | Metastatic Castration-sensitive Prostate Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targets, and regulatory pathway |
MoA Biomarker | biomarker source |
PK/PD Half-life | 3.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Influence of drug incorporation strategy on structure and release behavior of alginate beads: A mechanistic study.. Conventional excipients used in pharmaceutical formulations often exhibit limitations such as uncontrolled drug release and adverse patient responses, highlighting the need for improved drug delivery systems. Sodium alginate beads have been widely investigated as biocompatible carrie… |
Clinical Primary efficacy | ORR 57.1% |
Clinical ORR | 57.1% |
Clinical PFS | 16.16 |
Clinical OS | 34.07 |
Clinical Result source | ClinicalTrials.gov NCT01867710 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교